Laura Martano

Laura Martano

Alma Mater Studiorum Università di Bologna, Bologna, Emilia-Romagna, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
ICIrene Capelli
Irene Capelli
LMLaura Martano
Laura Martano
GBGian Marco Berti
Gian Marco Berti
GVGisella Vischini
Gisella Vischini
SLSarah Lerario
Sarah Lerario
Gaetano La MannaGaetano La Manna
Gaetano La Manna
Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by mutations in the GLA gene, leading to α-galactosidase A deficiency and subsequent accumulation of glycosphingolipids, including globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3), in multiple organs. This accumulation can result in multisystemic disease and life-threatening complications. FD presents with a broad phenotypic spectrum, ranging from the classic form, with early and severe symptoms, to a later-onset form with variable manifestations. The severity of the disease in females is more variable due to X-chromosome inactivation (XCI). Renal involvement is a key feature, and kidney biopsy remains a valuable tool for diagnosing FD and assessing the extent of nephropathy. Although molecular genetic testing is the gold standard for diagnosis, kidney biopsy aids in confirming renal involvement, detecting coexisting conditions, and determining the pathogenicity of variants of uncertain significance (VUSs). Moreover, kidney biopsy can serve as a prognostic tool by identifying early markers of nephropathy, such as foot process effacement and glomerular sclerosis, which predict disease progression. Emerging technologies, including machine learning, offer the potential to enhance the analysis of renal histology, improving diagnostic accuracy and patient stratification. Despite the challenges posed by overlapping diseases and potential misdiagnoses, kidney biopsy remains an essential component of FD diagnosis and management, facilitating early detection, the monitoring of disease progression, and the evaluation of therapeutic responses.

16 December 2024 in Seminars in Dialysis
Verified
Journal Article
Open access
FZFulvia Zappulo
Fulvia Zappulo
LMLaura Martano
Laura Martano
IUInes Ullo
Ines Ullo
VCVeronica Catalano
Veronica Catalano
SDSara Donini
Sara Donini
Gaetano La MannaGaetano La Manna
Gaetano La Manna
Extracorporeal therapies could be required for treatment of life‐threatening severe acute intoxication. We present the case of an 82‐year‐old patient admitted to our Nephrology Unit because of metformin‐associated lactic acidosis (MALA) and acute kidney injury (AKI stage III AKIN criteria). The patient also presented severe intoxication of digoxin and apixaban. The electrocardiogram presented a junctional escape rhythm with atrial fibrillation (AF) and lateral ST‐segment depression that, despite fab‐fragments' administration, has not regress. Due to patient's hemodynamic instability, an 8 h of sustained low‐efficiency diafiltration (SLED) was prescribed. This treatment allowed to reduce serum concentration of apixaban and digoxin. Similarly, patient's hemodynamic and ECG trace improved with the resolution of junctional rhythm and persistence of AF. Even if continuous renal replacement therapy (CRRT) is the first choice in critical ill patients, SLED could represent a valid option for patients without indication to ICU.

6 December 2023 in Journal Of Nephrology
Verified
Journal Article
Open access
PDF file
GVGisella Vischini
Gisella Vischini
SSSerena Speciale
Serena Speciale
APAgnieszka Przygocka
Agnieszka Przygocka
LMLaura Martano
Laura Martano
Gaetano La MannaGaetano La Manna
Gaetano La Manna
OBOlga Baraldi
Olga Baraldi